Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer

Medical Oncology

Volumn 28, Issue SUPPL. 1, 2011, Pages

  Li, Xi Ru ^a   Liu, Mei ^a   Zhang, Yan Jun ^a   Wang, Jian Dong ^a   Zheng, Yi Qiong ^a   Li, Jie ^a   Ma, Bing ^a   Song, Xin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cyclin D1; Docetaxel; Epirubicin; Locally advanced breast cancer; Neoadjuvant chemotherapy; nm23 H1

Indexed keywords

CYCLIN D1; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; NUCLEOSIDE DIPHOSPHATE KINASE A; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

EID: 84655170220     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9676-z     Document Type: Article

References (41)

1. B Fisher A Brown E Mamounas 1997 Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18 J Clin Oncol 15 2483 2493 (Pubitemid 27289876)
2. P Rastogi SJ Anderson HD Bear 2008 Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27 J Clin Oncol 26 778 785 (Pubitemid 351264391)
3. B Fisher J Bryant N Wolmark 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685 (Pubitemid 28363030)
4. HM Kuerer LA Newman TL Smith 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 469 (Pubitemid 29075229)
5. AU Buzdar NK Ibrahim D Francis 2005 Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 3676 3685
6. V Guarneri K Broglio SW Kau 2006 Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 1037 1044 (Pubitemid 46638799)
7. JS Jeruss EA Mittendorf SL Tucker 2008 Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy J Clin Oncol 26 246 252
8. GF Schwartz AJ Meltzer EA Lucarelli 2005 Breast conservation after neoadjuvant chemotherapy for stage II carcinoma of the breast J Am Coll Surg 201 327 334 (Pubitemid 41206769)
9. DG Tiezzi JM Andrade A Ribeiro-Silva 2007 HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination BMC Cancer 7 36
10. V Ganansia-Leymarie P Bischoff JP Bergerat 2003 Signal transduction pathways of taxanes-induced apoptosis Curr Med Chem Anticancer Agents 3 291 306 (Pubitemid 36758303)
11. BK Sinha PM Politi 1990 Anthracyclines Cancer Chemother Biol Response Modif 11 45 57
12. G Pohl M Rudas S Taucher 2003 Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy Breast Cancer Res Treat 78 97 103 (Pubitemid 36223022)
13. AE Ring IE Smith S Ashley 2004 Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer Br J Cancer 91 2012 2017 (Pubitemid 40128767)
14. G [tmp] MacGrogan L Mauriac M Durand 1996 Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi Br J Cancer 74 1458 1465 (Pubitemid 26370740)
15. RJ Burcombe A Makris PI Richman 2005 Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer Br J Cancer 92 147 155 (Pubitemid 40188448)
16. M Colleoni G Viale D Zahrieh 2008 Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy Ann Oncol 19 465 472 (Pubitemid 351325666)
17. JL Hayward PP Carbone JC Heusen 1977 Assessment of response to therapy in advanced breast cancer Br J Cancer 35 292 298
18. A Goldhirsch JH Glick RD Gelber 2001 Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer J Clin Oncol 19 3817 3827 (Pubitemid 32880060)
19. GG [tmp] McIntosh JJ Anderson I Milton 1995 Determination of the prognostic value of cyclin D1 overexpression in breast cancer Oncogene 11 885 891
20. M Colleoni G Viale D Zahrieh 2004 Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment Clin Cancer Res 10 6622 6628 (Pubitemid 39346559)
21. TW Jacobs AM Gown H Yaziji 1999 Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States food and drug administration approved scoring system J Clin Oncol 17 1983 1987 (Pubitemid 29318825)
22. S Amat F Penault-Llorca H Cure 2002 Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy Int J Oncol 20 791 796
23. T Petit M Wilt M Velten 2004 Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy Eur J Cancer 40 205 211 (Pubitemid 38077022)
24. M Tewari A Krishnamurthy HS Shukla 2008 Predictive markers of response to neoadjuvant chemotherapy in breast cancer Surg Oncol 17 301 311
25. DS Subramaniam C Isaacs 2005 Utilizing prognostic and predictive factors in breast cancer Curr Treat Options Oncol 6 147 159 (Pubitemid 40392701)
26. L Wang Z Jiang M Sui 2009 The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study BMC Cancer 9 226
27. G von Minckwitz HP Sinn G Raab 2008 Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast Breast Cancer Res 10 R30
28. MG Daidone S Veneroni E Benini 1999 Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer Int J Cancer 84 580 586
29. F Penault-Llorca C Abrial I Raoelfils 2008 Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy Oncologist 13 1235 1245
30. P Collecchi E Baldini P Giannessi 1998 Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers Eur J Cancer 34 1701 1704 (Pubitemid 28474222)
31. J Chang M Ormerod TJ Powles 2000 Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma Cancer 89 2145 2152
32. A Vincent-Salomon A Rousseau M Jouve 2004 Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy Eur J Cancer 40 1502 1508 (Pubitemid 38757737)
33. M Colleoni E Orvieto F Nolé 1999 Prediction of response to primary chemotherapy for operable breast cancer Eur J Cancer 35 574 579 (Pubitemid 29192965)
34. IF Faneyte JG Schrama JL Peterse 2003 Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome Br J Cancer 88 406 412 (Pubitemid 36308152)
35. J Akervall E Brun M Dictor 2001 Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck-preliminary report Acta Oncol 40 505 511
36. R Samejima Y Kitajima S Yunotani 1999 Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma Anticancer Res 19 5515 5521 (Pubitemid 30093319)
37. CR Berney RJ Fisher J Yang 1999 Protein markers in colorectal cancer: predictors of liver metastasis Ann Surg 230 179 184 (Pubitemid 30191883)
38. N Iizuka K Hirose T Noma 1999 The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma Br J Cancer 81 469 475 (Pubitemid 29458801)
39. A Bottini A Berruti A Bersiga 1996 Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours Anticancer Res 16 3105 3110 (Pubitemid 26390257)
40. A Bottini A Berruti A Bersiga 2000 p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients Clin Cancer Res 6 2751 2758 (Pubitemid 30482114)
41. DG Tiezzi JM De Andrade FJ Candido dos Reis 2006 Apoptosis induced by neoadjuvant chemotherapy in breast cancer Pathology 38 21 27 (Pubitemid 43259247)